Diaverum
 | |
| Privately held | |
| Industry | Healthcare |
Key people | Dag Andersson, President and CEO |
| Services | Dialysis and renal care |
Number of employees | 9,000 (2016) |
| Website | www.diaverum.com |
Diaverum is a provider of renal healthcare with about 300 clinics in Latin America, Europe, Asia, Australia and the Middle East.[1]
History
Diaverum was originally part of the Swedish company Gambro, founded in Lund, Sweden in 1964.[2] Gambro opened its first dialysis clinic in Lund in 1991. The clinic activities expanded under the name Gambro Healthcare and by 2005 the company managed 150 dialysis clinics worldwide. Gambro Healthcare was divested from Gambro in 2007 and taken over by Bridgepoint Capital, a major private healthcare investor in Europe, and the company management. The name Diaverum was adopted in 2008. Today, Diaverum is led by Dag Andersson, President and CEO and his executive team.[3]
It established a contract with IWantGreatCare in 2012 to allow its customers to provide feedback. Responses are collected and analysed in multiple languages for an initial roll out covering the UK and Spain.
Since the Health and Social Care Act 2012 came into force in April 2013 the company has been awarded three contracts worth at least £150m.[4]
Service offer
Diaverum describes itself as integrated renal care provider offering renal care from preventive and early stage to renal replacement therapies:
- In-clinic haemodialysis
- Peritoneal dialysis
- Preventive care
- Other medical services such as vascular access
Medical research
Diaverum also conducts clinical research, under the direction of the company’s scientific director Giovanni FM Strippoli.[5] The research focuses on preventing or minimising the risks for dialysis, making dialysis more effective, finding solutions to minimise risks of dialysis side effects, and finding proof of the efficacy of dialysis related drugs. The research has been published in international medical journals such as The Lancet,[6] the New England Journal of Medicine [7] and the Clinical Journal of the American Society of Nephrology.[8]
External links
- Diaverum Website (2015): http://diaverum.com/en-DE/Home/
- Diaverum clinics (2015): http://diaverum.com/en-DE/Clinic-finder/
- Dag Andersson CEO blog (2015): http://dagandersson.com/
- Website Bridgepoint (2015): http://www.bridgepoint.eu/home
- Strippoli, G. Palmer, S. C. et al (2013): Oral disease in adults treated with hemodialysis: prevalence, predictors, and association with mortality and adverse cardiovascular events: the rationale and design of the ORAL Diseases in hemodialysis (ORAL-D) study, a prospective, multinational, longitudinal, observational, cohort study. BMC Nephrology 2013, 14:90. Online available: http://www.biomedcentral.com/1471-2369/14/90
- Maione, A., Strippoli, G. et al (2007): Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. JNephrol 2007; 20 (6). Online available: http://www.sin-italy.org/web/procedure/protocollo.cfm?List=WsIdEvento,WsIdRisposta,WsRelease&c1=00141&c2=3&c3=1
- Strippoli, G. & Clinical Evaluation of the DOse of Erythropoietins Study Group (2010): Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010, 11:70. Online available: http://www.trialsjournal.com/content/11/1/70
References
- ↑ Diaverum company profile (2015)
- ↑ Gambro history, Gambro (2015)
- ↑ Executive team, Diaverum (2015)
- ↑ "Private firms on course to net £9bn of NHS contracts". Guardian. 19 November 2014. Retrieved 20 November 2014.
- ↑ Scientific research, Diaverum (2015)
- ↑ Strippoli, G., Tognoni, G. et al (2007): Haemoglobin targets: we were wrong, time to move on. The Lancet 3 February 2007. Online available: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60165-2/abstract
- ↑ Strippoli, G. & Craig, C. J. (2009): Sunset for Statins after AURORA? N Engl J Med April 2, 2009, 360:1455-1457, DOI: 10.1056/NEJMe0901067.
- ↑ Strippoli, G. & Collaborative Depression and Sexual Dysfunction (CDS) in Hemodialysis Working Group (2012): Sexual Dysfunction in Women with ESRD Requiring Hemodialysis. CJASN March 12, 2012.